JPRN-UMIN000001858已完成2 期
Multicenter phase II study of S-1 plus Weekly Cisplatin in first-line treatment of unresectable or reccurent gastric cancer - The efficacy and safety of S-1 and weekly cisplatin combination therapy compared with the standard SP
Tsukuba Cancer Clinical Trial Group0 个研究点目标入组 70 人开始时间: 2009年4月7日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Serious drug hypersensitivity or a history of drug allergy 2)Administered of flucytosine, phenytoin or warfarin potassium 3)Active infections 4)Serious complications (e.g., interstitial pneumonitis, pulmonary fibrosis, uncontrolled diabetes mellitus, renal failure or hepatic failure) 5)Uncontrolled watery diarrhea 6)Severe ascites or pleural effusion 7)Active double cancer 8)Pregnant women, possibly pregnant women, women wishing to become pregnant, and nursing mothers 9)Men who are currently attempting to conceive children 10)Judged ineligible for participation in the study by the investigator for safety reasons
研究者
相似试验
已完成
2 期
A Multicenter phase II study of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanved non-squamous non-small cell lung cancerJPRN-UMIN000007386Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine28
已完成
2 期
Multicenter phase II study of second-line S-1 monotherapy in patients with gemcitabine-refractory advanced biliary tract cancerGemcitabine-refractory advanced biliary tract cancerJPRN-UMIN000001614Faculty of Medicine, University of Tokyo22
未知
2 期
Phase II Study of S-1 plus LV (1 week on and 1 week off) as First-line Treatment for Patients with metastatic colorectal cancer.Colorectal CancerJPRN-jRCT2080220727Taiho Pharmaceutical Co., Ltd.
已完成
2 期
Phase II study of 3-weeks cycle of S-1 as first-line for advanced pancreatic cancer (PACS-3)advanced pancreatic cancerJPRN-UMIN000011179Gifu University Hospital70
招募中
2 期
A phase II trial of sequential treatment from cisplatin-etoposide therapy (PE) to irinotecan hydrochloride + amrubicin hydrochloride therapy with concomitant use of G-CSF nartograstim in patients with extensive-stage small cell lung cancer or advanced large cell neuroendocrine carcinoma (LCNEC)Extensive-stage small cell lung cancer and stage IIIB/IV large cell neuroendocrine carcinoma (LCNEC)JPRN-UMIN000006497Department of Respiratory Medicine Kitasato University School of Medicine31